Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS in Action

The ESMO-MCBS uses a structured and disciplined approach to deriving estimates of clinically meaningful benefit of cancer medicines from published data and can be used in a range of settings, including:

Grading derived from the ESMO-MCBS provides a backbone for value evaluations of cancer medicines and can help public policy-makers in the advancement of ‘accountability for reasonableness’ in resource allocation deliberations. It is being used as part of HTA processes in a growing number of countries.

  • ESMO has developed a methodology template designed to empower health systems globally to make efficient spending decisions allowing comprehensive coverage of cancer services for entire populations. The generalisable model, was originally developed to help the country of Kazakhstan update and rationalise its national list of essential cancer medicines and treatment protocols. The evidence-based methodology for the evaluation of national medication formularies, rely on freely accessible, validated tools to help decision-makers maximise the impact of their cancer programmes by investing in care that offers the highest value for money. In a four-phase approach a comprehensive list of all anticancer medicines used in Kazakhstan was created and cross-checked against the WHO Model List of Essential Medicines, therapeutic indications from the European Medicines Agency (EMA) database and, where applicable, scores on the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) were provided. National treatment protocols for different cancer types were equally compared with recommendations from the ESMO Clinical Practice Guidelines. Following an expert review of the findings, a summary report was submitted to the government of Kazakhstan to inform further action.

The data enclosed in ESMO-MCBS scoring can help clinicians weigh the relative merits of competing relevant therapeutic options and may also be of benefit in explaining the relative merit of therapeutic options to patients and their families. This information may be especially helpful when treatments incorporate substantial out-of-pocket costs.

For cancer therapies, the ESMO-MCBS scale provides a clear, well-structured and validated mechanism to indicate the magnitude of clinical benefit, in addition to the level of evidence, that can inform both national and international guidelines.

The ESMO-MCBS may be of use to editors, peer reviewers and commentators in considering the clinical significance of research findings from randomised clinical studies, cohort studies and meta-analyses with statistically significant positive findings.

The ESMO-MCBS is a powerful tool to teach a disciplined and validated approach to data interpretation. It is especially valuable for oncologists in training and for application in journal club discussion.

  • The ESMO-MCBS has been presented inside and outside Europe and in educational workshops for stakeholders, patient (advocates), pharma representatives and Health Technology Assessment (HTA) bodies to increase knowledge sharing of the tool. Additionally, it is being used in oncology training programmes and journal club presentations, modelling a structured approach to data interpretation in the evaluation of clinical benefit.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.